4Pisters KM ,Vallieres E, Crowley JJ,et al. Surgery with or without preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer:Southwest Oncology Group Trim $9900 ,an intergroup, randomized, phase m trial [J]. Clin Oncol, 2010,28 ( 11 ) : 1843-1849.
5Zhang H, Berezov A,Wang Q ,etal. ErbB receptors: from oncogenes to targeted cancer therapies [J]. J Clin Invest,2007,117 (8) : 2051- 2058. Chinese.
6Arfaoui A1 ,Kriaa L,Znaidi N,et al. Over-expression of EGFR is close- ly correlated to poor prognosis in Tunisian patients with non-small cell lung adenocarcinoma [J]. J Immunoassay Immunochem,2014,35 (3):256-68.
8Zhu J ,Wang "Y ,Duan J. DNA Mcthylation status of Wnt antagonist SFRP5 can predict the response to the EGFR-tymsine kinase in- hibitor therapy in non-small cell lung cancer [J]. Exp Clin Cancer Res,2012,31:80.
9Stella GM, Luisetti M ,Inghilleri S,et al. Targeting EGFR in non- small-cell lung cancer: Lessons,experiences,strategies [J]. Respir Med ,2012,106(2) : 173-183.
10Otto C, Csanadi A, Fisch P, et al. Molecular modeling and descrip- tion of a newly characterized activating mutation of the EGFR gene in non-small cell lung cancer [J]. Diagn Patho1,2012,7(1 ) : 146.
